Rami Manochakian: FDA Approves Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer Based on TRUST Trials

Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared on X:

“Hot Off The Press

U.S. FDA approves Taletrectinib for locally advanced or metastatic ROS1+ non-small cell Lung Cancer.

Approval based on TRUST I and II Trials.

– ORR:
85-90% for treatment-naive patients
52-62% or TKI-pretreated patients”

Read the full article.

Taletrectinib

More posts featuring Rami Manochakian on OncoDaily.

Insight

cancer FDA Lung cancer North American Neuroendocrine Tumor Society NSCLC OncoDaily Oncology Rami Manochakian Taletrectinib trust TRUST trial U.S. FDA

Rami Manochakian: FDA Approves Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer Based on TRUST Trials

“Hot Off The Press

U.S. FDA approves Taletrectinib for locally advanced or metastatic ROS1+ non-small cell Lung Cancer.

Approval based on TRUST I and II Trials.

– ORR: 85-90% for treatment-naive patients 52-62% or TKI-pretreated patients”

– ORR:
85-90% for treatment-naive patients
52-62% or TKI-pretreated patients”